JP2013532130A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532130A5
JP2013532130A5 JP2013510364A JP2013510364A JP2013532130A5 JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5 JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5
Authority
JP
Japan
Prior art keywords
represented
compound
pharmaceutically acceptable
acceptable salt
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510364A
Other languages
English (en)
Japanese (ja)
Other versions
JP5715241B2 (ja
JP2013532130A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036701 external-priority patent/WO2011143669A2/en
Publication of JP2013532130A publication Critical patent/JP2013532130A/ja
Publication of JP2013532130A5 publication Critical patent/JP2013532130A5/ja
Application granted granted Critical
Publication of JP5715241B2 publication Critical patent/JP5715241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510364A 2010-05-14 2011-05-16 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 Active JP5715241B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33499110P 2010-05-14 2010-05-14
US61/334,991 2010-05-14
US37074510P 2010-08-04 2010-08-04
US61/370,745 2010-08-04
US37586310P 2010-08-22 2010-08-22
US61/375,863 2010-08-22
PCT/US2011/036701 WO2011143669A2 (en) 2010-05-14 2011-05-16 Compositions and methods for treating neoplasia, inflammatory disease and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015049960A Division JP5937247B2 (ja) 2010-05-14 2015-03-12 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013532130A JP2013532130A (ja) 2013-08-15
JP2013532130A5 true JP2013532130A5 (enExample) 2014-11-06
JP5715241B2 JP5715241B2 (ja) 2015-05-07

Family

ID=49052897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013510364A Active JP5715241B2 (ja) 2010-05-14 2011-05-16 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
JP2015049960A Active JP5937247B2 (ja) 2010-05-14 2015-03-12 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015049960A Active JP5937247B2 (ja) 2010-05-14 2015-03-12 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法

Country Status (1)

Country Link
JP (2) JP5715241B2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3182721B2 (ja) 1997-08-06 2001-07-03 理兆 上田 自動車のペダル装置
JP5913292B2 (ja) * 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド 代謝を調節する組成物および方法
US8981083B2 (en) 2010-05-14 2015-03-17 Dana Farber Cancer Institute, Inc. Compositions and methods for treating neoplasia, inflammatory disease and other disorders
MX2014015986A (es) * 2012-06-25 2016-02-11 Oncoethix Gmbh Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
US20160158246A1 (en) * 2013-08-06 2016-06-09 Oncoethix Gmbh Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
KR20160072261A (ko) * 2013-11-08 2016-06-22 다나-파버 캔서 인스티튜트 인크. 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
RU2722179C2 (ru) 2014-02-28 2020-05-28 Тэнша Терапеутикс, Инк. Лечение состояний, ассоциированных с гиперинсулинемией
AU2016283020A1 (en) * 2015-06-26 2018-01-04 Tensha Therapeutics, Inc. Treatment of nut midline carcinoma
JP2018526424A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド アセトアミドチエノトリアゾロジアゼピンおよびこれらの使用
US11306105B2 (en) * 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
PE20181068A1 (es) * 2015-10-02 2018-07-04 Dana Farber Cancer Inst Inc Terapia de combinacion de inhibidores de bromodominios y bloqueo de puntos de control
ES2882066T3 (es) * 2016-02-15 2021-12-01 Univ Michigan Regents 1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
EP3555059A1 (en) * 2016-12-16 2019-10-23 H. Hoffnabb-La Roche Ag Process for the manufacture of diazepine derivatives
CN109503618A (zh) * 2017-09-14 2019-03-22 成都海创药业有限公司 一种brd4抑制剂
MX2020013608A (es) * 2018-06-13 2021-03-09 Worg Pharmaceuticals Hangzhou Co Ltd Preparacion de derivados de triazepina condensados y su uso como inhibidores de bet.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1227555A (zh) * 1996-06-12 1999-09-01 日本烟草产业株式会社 细胞因子生成抑制剂、三氮䓬化合物及其中间体
US7589167B2 (en) * 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
ES2545666T3 (es) * 2003-02-27 2015-09-14 Abbvie Inc. 5,10-Dihidro-11H-dibenzo[b,e][1,4]diazepin-11-ona como inhibidores de quinasa
EP2239264A4 (en) * 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
KR20120097508A (ko) * 2009-11-05 2012-09-04 글락소스미스클라인 엘엘씨 벤조디아제핀 브로모도메인 억제제

Similar Documents

Publication Publication Date Title
JP2013532130A5 (enExample)
JP2011105738A5 (enExample)
JP2012107057A5 (enExample)
JP2012111758A5 (enExample)
JP2009149903A5 (enExample)
JP2013532687A5 (enExample)
JP2011518833A5 (enExample)
JP2019194236A5 (enExample)
JP2011168603A5 (enExample)
JP2012081521A5 (enExample)
JP2011510079A5 (enExample)
JP2013032389A5 (enExample)
JP2010529196A5 (enExample)
JP2009535462A5 (enExample)
JP2015522045A5 (enExample)
JP2014221779A5 (enExample)
JP2011520976A5 (enExample)
JP2013173781A5 (enExample)
JP2013541578A5 (enExample)
JP2018521020A5 (enExample)
JP2011170856A5 (enExample)
JP2012094862A5 (enExample)
JP2011519871A5 (enExample)
JP2011037885A5 (enExample)
JP2015199738A5 (enExample)